Benjamin Swanson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Benjamin Swanson has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Michael A. Hollingsworth
Eppley Institute for Research in Cancer and Allied Diseases, Fred & Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, USA
52 shared publications - Paul M. Grandgenett
Eppley Institute for Research in Cancer and Allied Diseases, Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA
52 shared publications - Thomas C. Caffrey
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska
52 shared publications - Adrian R. Black
Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA
39 shared publications - Brandy R. Murray
Department of Chemistry and Biochemistry, California State University Fresno, Fresno, California
39 shared publications - Christabelle Rajesh
Medical University of South Carolina 4 Department of Biochemistry and Molecular Biology Charleston, South Carolina
39 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors
Unique identifications via mass spectrometry.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors
Unique identifications via mass spectrometry.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors
Pancreatic ductal adenocarcinoma (PDAC) evolves through precursors, yet the protein programs governing early progression remain poorly defined. We applied Deep Visual Proteomics (DVP)—integrating computational pathology, laser microdissection, and mass spectrometry (MS)—to profile normal ducts, acinar-to-ductal metaplasia (ADM), low-grade (LG) and high-grade (HG) pancreatic intraepithelial neoplasia (PanIN), and invasive carcinoma from organ donors and patients with PDAC. Quantifying 9,181 proteins from ∼100 cells per region, we uncovered a molecular field effect in histologically normal ducts and proteomic divergence of LG-PanINs by cancer context. We identified four stage-associated molecular programs. Stress adaptation and immune engagement emerged early in cancer-associated normal ducts. Metabolic reprogramming initiated in normal ducts and intensified across PanIN progression. Mitochondrial remodeling became prominent in HG-PanINs before invasion. MS detected KRAS hotspot mutant peptides within incidental precursor lesions from cancer-free individuals. These findings demonstrate that molecular reprogramming precedes histologic transformation, creating opportunities for earlier detection of lethal cancer.Significance:Artificial intelligence (AI)–guided DVP represents the first in-depth assessment of the proteomic landscapes observed during the multistep progression of pancreatic adenocarcinoma, including histologically normal ducts, ADM, and LG- and HG-PanIN lesions. These data represent a unique resource of candidate biomarkers and interception targets against this lethal disease.See related commentary by Yang and Fan, p. 1255
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors
Pancreatic ductal adenocarcinoma (PDAC) evolves through precursors, yet the protein programs governing early progression remain poorly defined. We applied Deep Visual Proteomics (DVP)—integrating computational pathology, laser microdissection, and mass spectrometry (MS)—to profile normal ducts, acinar-to-ductal metaplasia (ADM), low-grade (LG) and high-grade (HG) pancreatic intraepithelial neoplasia (PanIN), and invasive carcinoma from organ donors and patients with PDAC. Quantifying 9,181 proteins from ∼100 cells per region, we uncovered a molecular field effect in histologically normal ducts and proteomic divergence of LG-PanINs by cancer context. We identified four stage-associated molecular programs. Stress adaptation and immune engagement emerged early in cancer-associated normal ducts. Metabolic reprogramming initiated in normal ducts and intensified across PanIN progression. Mitochondrial remodeling became prominent in HG-PanINs before invasion. MS detected KRAS hotspot mutant peptides within incidental precursor lesions from cancer-free individuals. These findings demonstrate that molecular reprogramming precedes histologic transformation, creating opportunities for earlier detection of lethal cancer.Significance:Artificial intelligence (AI)–guided DVP represents the first in-depth assessment of the proteomic landscapes observed during the multistep progression of pancreatic adenocarcinoma, including histologically normal ducts, ADM, and LG- and HG-PanIN lesions. These data represent a unique resource of candidate biomarkers and interception targets against this lethal disease.See related commentary by Yang and Fan, p. 1255
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors
Antibodies used in multiplex immunofluorescence.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors
Antibodies used in multiplex immunofluorescence.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S12 from AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors
Fig. S1 | Cohort overview Fig. S2 | Study quality control overview Fig. S3 | Mass spectrometry performance across processing batches Fig. S4 | Intra-patient regional variation in TP53 and DCLK1 protein abundance Fig. S5 | Distinct protein abundance patterns across pancreatic tumorigenesis Fig. S6 | Detailed protein abundance patterns associated with key molecular programs underlying the cancer field effect and multistep pancreatic neoplasia Fig. S7 | Metabolic reprogramming in PanIN lesions Fig. S8 | PDAC lineage markers across the investigated trajectory Fig. S9 | Integration of spatial proteomics and transcriptomics data on the PDAC tumorigenesis Fig. S10 | Orthogonal validation of protein markers by multiplex immunofluorescence (mIF) staining Fig. S11 | Proteomics- and digital droplet PCR (ddPCR)-based identification of altered KRAS peptides Fig. S12 | Systematic exploration of image clustering parameters using H-optimus-0
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S12 from AI-Powered Deep Visual Proteomics Reveals Critical Molecular Transitions in Pancreatic Cancer Precursors
Fig. S1 | Cohort overview Fig. S2 | Study quality control overview Fig. S3 | Mass spectrometry performance across processing batches Fig. S4 | Intra-patient regional variation in TP53 and DCLK1 protein abundance Fig. S5 | Distinct protein abundance patterns across pancreatic tumorigenesis Fig. S6 | Detailed protein abundance patterns associated with key molecular programs underlying the cancer field effect and multistep pancreatic neoplasia Fig. S7 | Metabolic reprogramming in PanIN lesions Fig. S8 | PDAC lineage markers across the investigated trajectory Fig. S9 | Integration of spatial proteomics and transcriptomics data on the PDAC tumorigenesis Fig. S10 | Orthogonal validation of protein markers by multiplex immunofluorescence (mIF) staining Fig. S11 | Proteomics- and digital droplet PCR (ddPCR)-based identification of altered KRAS peptides Fig. S12 | Systematic exploration of image clustering parameters using H-optimus-0